课题基金 / 基金详情

Harnessing promoter synergism for the enhancement of gene expression

Harnessing promoter synergism for the enhancement of gene expression
利用启动子协同作用增强基因表达
批准号:
7271063
负责人:
MAGDOLNA G SEBESTYEN
金额:
$30.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-05-01 至 2009-04-30
关键词:
5-bromo-4-chloro-3-indolyl beta-galactosideAddressAffectAlkaline PhosphataseAmyotrophic Lateral SclerosisAnemiaAnimal ModelAnimalsAreaArterial Occlusive DiseasesCanis familiarisCaviaClinicClinicalCollaborationsCrigler-Najjar SyndromeCytomegalovirusDNADNA SequenceDNA deliveryDataDetectionDevelopmentDevelopment PlansDiseaseDoseDuchenne muscular dystrophyDystrophinElementsErythropoietinExperimental DesignsFoundationsFranceFutureGalactosidaseGene DeliveryGene ExpressionGenerationsGenesGenetic TranscriptionGoalsHarvestHistocytochemistryHumanHybridsImmuneInheritedInjection of therapeutic agentIntellectual PropertyLeadLicensingLimb structureLocationLongevityMM form creatine kinaseMacaca fascicularisMacaca mulattaMethodsMolecularMusMuscleMuscular DystrophiesNumbersOryctolagus cuniculusOutcomePathway interactionsPatientsPeripheralPhasePhase I Clinical TrialsPhase II Clinical TrialsPhysiologicalPlasmid Cloning VectorPlasmidsPlayProceduresPropertyProteinsPurposeRangeRattusReporter GenesResearchResearch PersonnelResearch Project GrantsRoleSerumSkeletal MuscleStaining methodStainsStudy SubjectSumTechnologyTestingTherapeuticTherapeutic EffectTherapeutic StudiesTimeTimeLineTissuesTranscriptional RegulationTransgenesTreatment CostTreatment ProtocolsVeinsWorkalpha 1-Antitrypsin Deficiencybasedaydesigndesireenzyme activityexpression vectorgene therapyhuman studyimmunogenicimprovedin vivointerestintravenous injectionmdx mousenon-viral gene therapynonhuman primateplasmid DNApre-clinicalpreclinical studypromoterresearch studysynergismtherapeutic genetransgene expressionvector

项目摘要

项目成果

MAGDOLNA G SEBESTYEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have invented a safe and simple method for naked DNA delivery into limb muscles, the hydrodynamic limb vein injection, which is a clinically viable procedure holding great promise for the treatment of various inherited and acquired diseases. This technology increased the efficiency of naked DNA delivery to a level that makes its transfer to the clinic realistic. However, a significant increase in expression levels would make treatments more economical and would also make the approach amenable for a broader range of disorders. For this Phase I project we propose to test the use of the combination of two promoters that we found to interact in trans in a synergistic way in rhesus skeletal muscle leading to over 10-fold enhancement in gene expression. As the first steps toward characterizing the phenomenon and identifying the mechanism behind it our specific aims will assess whether the synergistic effect: (1) can be reproduced in several species commonly used for in vivo gene delivery studies, (2) requires the presence of the promoters in trans, or new constructs containing the promoters in cis on a single plasmid would also show enhanced expression, (3) can sustain elevated expression levels long-term, (4) increases the percentage of myofibers with detectable (therapeutic) level of transgene expression besides increasing the overall amount of gene product. Our long- term goals for Phase II studies are to identify the sequence elements that are responsible for the synergistic effect and the mechanism by which they interact and use the information for the rational design of new expression constructs. A 10-fold increase in expression efficiency would have a remarkable effect on how economical naked DNA-based gene therapy may become. It would facilitate the transition of many current non-viral gene therapy research projects to the clinic. There are a great number of inherited and acquired diseases that could benefit from gene therapy. The intravenous injection of naked DNA into limb muscles has the potential to become a clinically acceptable gene delivery procedure. We plan to evaluate a unique approach to further improve expression efficiency in order to make this technology applicable for a broader range of diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein-free regulation of erythropoietin expression by a drug-sensing riboswitch
  • 批准号:
    7537692
  • 项目类别:
  • 资助金额:
    $15.51万
  • 财政年份:
    2008
  • 负责人:
    MAGDOLNA G SEBESTYEN
  • 依托单位:
Gene therapy treatment for severe anemia
  • 批准号:
    6882752
  • 项目类别:
  • 资助金额:
    $50.36万
  • 财政年份:
    2002
  • 负责人:
    MAGDOLNA G SEBESTYEN
  • 依托单位:
Gene therapy treatment for severe anemia
  • 批准号:
    7095281
  • 项目类别:
  • 资助金额:
    $24.07万
  • 财政年份:
    2002
  • 负责人:
    MAGDOLNA G SEBESTYEN
  • 依托单位:
Gene therapy treatment for severe anemia
  • 批准号:
    6952453
  • 项目类别:
  • 资助金额:
    $51.6万
  • 财政年份:
    2002
  • 负责人:
    MAGDOLNA G SEBESTYEN
  • 依托单位:
海外基金